



1 SUPPLEMENTAL MATERIAL



2

3 **Suppl. Figure 1. Sub-population composition of T and NK cells from COVID-19 patients.**

4 **(A)** UMAP visualization for the subclustering of T and NK cells selected PBMC of 7 COVID-19 patients
 5 (18 samples obtained at days 0, 5 and 15 post admission) and 6 healthy controls. Twelve major sub-
 6 populations were identified. **(B)** UMAP visualization of sixteen major T cell marker genes used to validate
 7 sub-populations annotation. **(C)** Heatmap representation of the normalized expression in each individual T-
 8 cell subpopulation for the top 74 genes identified as sub-population specific markers using the Seurat
 9 ‘FindAllMarkers’ function.



10


11 **Suppl. Figure 2. Sub-population composition of B cells from COVID-19 patients.**

12 (A) UMAP visualization of B cell sub-populations selected from 7 COVID-19 patients (18 samples
 13 obtained at days 0, 5 and 15 of admission) and 6 healthy controls. Four major sub-populations are identified.

14 (B) UMAP visualization of twelve major B-cell marker genes used to validate sub-population annotation.

15 (C) Heatmap representation of the normalized expression in each individual B-cell subpopulation for the
 16 top 37 genes identified as sub-population specific markers using the Seurat 'FindAllMarkers' function.


17



18

19 **Suppl. Figure 3. Sub-population composition of Myeloid cells from COVID-19 patients.**

20 **(A)** UMAP visualization of Myeloid cells subclustering selected from PBMC of 7 COVID-19 patients (18
 21 samples obtained at days 0, 5 and 15 of admission) and 6 healthy controls. Seven major sub-populations
 22 were identified. **(B)** UMAP visualization of twelve marker genes used to validate sub-population
 23 annotation. **(C)** Heatmap representation of the normalized expression in each Myeloid cell subpopulation
 24 for the top 50 genes identified as sub-population specific markers using the Seurat 'FindAllMarkers'
 25 function.




26


27 **Suppl. Figure 4. PBMC sub-population cell proportions**


28 Box and whisker plots for the proportion of cells for each subpopulation of T cells (A), B cells (B) and
 29 Myeloid cells (C) for samples in each clinical group; expressed as % of total PBMC. Lineage proportions
 30 at days 5 and 15 of COVID-19 patients classified based on the disease OS and grouped as Moderate(cyan)
 31 or Critical(purple). Corresponding values from healthy controls (red) and from all COVID-19 patients at
 32 admission (green) are provided as reference groups. Q-values for pairwise t-test between Critical and
 33 Moderate comparisons are provided when significant.

34

Legend: ■ Controls ■ Admission - Deceased ■ Admission - Alive ■ d5 - Deceased ■ d5 - Alive








41 **Suppl. Figure 5. Evolution of the transcriptional expression for enriched GO-terms.**

42 Differentially expressed genes contributing to GO term enrichment (indicated on the left axis and displayed
43 in Figure 4A) have been used to generate a Module Score representing the overall transcriptional expression
44 level for the specific category. Corresponding cell populations are listed at the bottom of the graph. Module
45 scores have been computed for the Day 0 and Day 5 time-points for each cell population and based on
46 “Deceased” and “Alive” COVID-19 patient outcomes separately. Control samples from healthy subjects
47 are included as reference. Sample groups are coloured according to the key on top of the graph. The
48 significance of the gene expression differences between “Deceased vs Alive” COVID-19 patients was
49 tested by comparing the corresponding Module Score distribution in every group of cells using a wilcoxon
50 rank-test approach ($q\text{-value} \leq 0.05$). To provide a sample-size free evaluation of the difference in
51 expression, Cohen’s d effect size estimation is shown above each significant variation observed.

52



53

54 **Suppl. Figure 6. COVID-19 WHO clinical ordinal scale correlates with chromatin stability of**
 55 **CD14+ monocytes.**

56 **(A)** The fraction of reads in peaks (FRIP) for CD14+ monocytes, a surrogate for chromatin stability, was
 57 plotted against the date of PBMC collection. The WHO ordinal scale for COVID-19 is shown for all patients
 58 at each timepoint. **(B)** Correlation of the FRIP with WHO clinical scale score for COVID-19. Samples are
 59 labeled according to the donor ID, day of collection and patient outcome.

716 More close peaks in deceased at Admission

Name	MOTIF	# of DAC with Motif	% of DAC with Motif	# random peaks with Motif	% of random peaks with Motif	# peaks at FDR > 50% with Motif	% peaks at FDR > 50% with Motif	p-value	FDR q-value
Group 1 - NFY									
NFY		282	49.3%	12676	27.4%	1356	34.9%	1.0E-28	< 5.0E-05
Group 2 - Sp1-like/KLF									
Sp1		297	51.9%	14991	32.4%	1592	40.9%	1.0E-21	< 5.0E-05
KLF3		308	53.9%	16188	34.9%	1642	42.2%	1.0E-19	< 5.0E-05
KLF1		404	70.6%	24860	53.7%	2318	59.6%	1.0E-16	< 5.0E-05
Klf9		238	41.6%	13083	28.2%	1256	32.3%	1.0E-11	< 5.0E-05
Sp5		409	71.5%	27005	58.3%	2488	64.0%	1.0E-10	< 5.0E-05
Klf4		189	33.0%	10073	21.7%	968	24.9%	1.0E-09	< 5.0E-05
KLF5		419	73.3%	29349	63.4%	2612	67.2%	1.0E-06	< 5.0E-05
KLF6		389	68.0%	26803	57.9%	2389	61.4%	1.0E-06	< 5.0E-05
Egr2		136	23.8%	7583	16.4%	671	17.3%	1.0E-05	< 5.0E-05
KLF10		193	33.7%	12843	27.7%	1100	28.3%	1.0E-03	5.6E-03
Maz		412	72.0%	30442	65.7%	2566	66.0%	1.0E-03	4.5E-03
Group 3 - E2F									
E2F4		273	47.7%	17136	37.0%	1629	41.9%	1.0E-07	< 5.0E-05
E2F7		101	17.7%	5881	12.7%	556	14.3%	1.0E-03	2.8E-03
E2F6		274	47.9%	18963	40.9%	1642	42.2%	1.0E-03	3.0E-03
E2F1		173	30.2%	11181	24.1%	996	25.6%	1.0E-03	3.3E-03
E2F3		298	52.1%	20918	45.2%	1818	46.8%	1.0E-03	3.3E-03
Group 4 - MYB									
MYB		369	64.5%	23351	50.4%	2064	53.1%	1.0E-11	< 5.0E-05
AMYB		302	52.8%	19292	41.6%	1815	46.7%	1.0E-07	< 5.0E-05
Group 5 - CRE									
CRE		114	19.9%	5183	11.1%	599	15.4%	1.0E-09	< 5.0E-05
Group 6 - HOX									
Hoxa9		362	63.3%	24219	52.3%	2058	52.9%	1.0E-07	< 5.0E-05
Hoxd10		190	33.2%	11890	25.7%	1069	27.5%	1.0E-04	3.0E-04
Group 7 - PBX									
Pbxox1		75	13.1%	3557	7.7%	308	7.9%	1.0E-05	1.0E-04
Pbx3		66	11.5%	3201	6.9%	263	6.8%	1.0E-04	4.0E-04
PBX1		30	5.2%	1072	2.3%	84	2.2%	1.0E-04	4.0E-04
MafA		165	28.9%	10200	22.0%	896	23.0%	1.0E-04	7.0E-04
Group 8 - ZNF189									
ZNF189		203	35.5%	12778	27.6%	1056	27.2%	1.0E-04	3.0E-04
Group 9 - LIM homeobox									
En1		271	47.4%	18020	38.9%	1600	41.1%	1.0E-04	3.0E-04
Isl1		280	49.0%	18856	40.7%	1596	41.0%	1.0E-04	4.0E-04
Lhx3		230	40.2%	15145	32.7%	1241	31.9%	1.0E-04	8.0E-04
Group 10 - Oct4:Sox17									
Oct4:Sox17		33	5.8%	1222	2.6%	65	1.7%	1.0E-04	3.0E-04
Group 11 - FOX									
Foxh1		115	20.1%	6695	14.5%	558	14.3%	1.0E-03	1.2E-03
Foxo1		288	50.4%	19992	43.2%	1734	44.6%	1.0E-03	2.3E-03
Group 12 - GATA									
GATA		32	5.6%	1394	3.0%	120	3.1%	1.0E-03	4.6E-03
Group 13 - TBX									
Tbx20		56	9.8%	2936	6.3%	258	6.6%	1.0E-03	5.8E-03
Group 14 - NKX									
Amt:Ahr		194	33.9%	12608	27.2%	1154	29.7%	1.0E-03	1.8E-03
Nkx2.2		336	58.7%	24193	52.2%	1946	50.0%	1.0E-03	5.9E-03
Nkx2.1		404	70.6%	29952	64.7%	2395	61.6%	1.0E-02	7.9E-03
Group 15 - ZNF669									
ZNF669		45	7.9%	2290	4.9%	170	4.4%	1.0E-02	9.4E-03


243 More open peaks in deceased at Admission

Name	MOTIF	# of DAC with Motif	% of DAC with Motif	# random peaks with Motif	% of random peaks with Motif	# peaks at FDR > 50% with Motif	% peaks at FDR > 50% with Motif	p-value	FDR q-value
Group 16 - IRF									
PU.1:IRF8		35	16.6%	2597	5.2%	346	9.8%	1.0E-08	< 5.0E-05
IRF8		43	20.4%	4285	8.7%	541	15.3%	1.0E-06	< 5.0E-05
IRF2		17	8.1%	1279	2.6%	193	5.5%	1.0E-04	1.5E-03
IRF4		37	17.5%	4711	9.5%	451	12.8%	1.0E-03	3.8E-03
Group 17 - CTCF									
CTCF		30	14.2%	3261	6.6%	324	9.2%	1.0E-04	1.8E-03
BORIS		53	25.1%	7884	15.9%	603	17.1%	1.0E-03	5.9E-03
Group 18 - MADS									
CArG		29	13.7%	3423	6.9%	236	6.7%	1.0E-03	5.2E-03

61 **Suppl Figure 7. Motif homology grouping for the 46 transcription factors enriched in DAC regions**
62 **of deceased patients at Admission.**

63 The 46 transcription factors significantly enriched in DAC regions of deceased patients at FDR <1% are
64 shown with their respective motif binding sequences in each row. Transcription factors were grouped based
65 on the sequence homology of their binding motif. The number and percentage of peaks with motifs
66 corresponding to the heatmap in figure 4D is shown for DAC, random peaks, and peaks at FDR > 50% in
67 the center columns. Uncorrected p -value and the FDR q -value for the contrast between DAC and random
68 regions is given in the last two columns.

69





70

71 **Suppl Figure 8. Chromatin accessibility at promoters of transcription factors with binding motifs**
 72 **enriched in repressed DAC regions of deceased COVID-19 patients.**

73 The mean chromatin accessibility at admission for patients retrospectively classified as Deceased or Alive
 74 are shown as black and green lines, respectively. Shades indicate the standard deviation of the mean for
 75 each group. At the bottom, a red bar denotes the regions contrasted in the “Deceased vs Alive” comparison
 76 with its corresponding p value.


77



78

79 **Suppl Figure 9. Non-random overlap between DAC for “Deceased” patient monocytes at admission**
 80 **with hospitalized COVID-19 GWAS loci.**

81 The evaluation of a non-random overlap between DAC regions with five significant/suggestive GWAS loci
 82 for hospitalized COVID-19 patients was performed using a permutation test. Genomic regions of equal
 83 length to the five GWAS loci were permuted across the human genome while the genomic position for all
 84 959 “Deceased vs Alive” DAC regions for monocytes at admission **(A)**, and for the subset of 481 DAC
 85 located in promoter regions **(B)**. The bar plots summarize the number of permuted GWAS loci overlapping
 86 a DAC region in the x-axis with the grey bars representing the density plotted in the y-axis. The black
 87 vertical line ($E_{V_{perm}}$) indicates the average number of permuted GWAS loci encompassing a DAC; the red
 88 line represents the 95 percentile of the distribution; and the green line ($E_{V_{obs}}$) highlights the number of
 89 GWAS loci with a DAC in our study.



90

91 **Suppl Figure 10. Differential DNA methylation among COVID-19 patients.**

92 **(A)** A total of 222,751 DMLs were identified for the “Deceased vs Alive” patient comparison at admission.

93 Hyper ($\Delta\beta > 0$) and hypomethylated ($\Delta\beta \leq 0$) CpGs were plotted against their corresponding p values. The

94 color gradient indicates the density of CpGs. **(B)** AreasStats of hyper ($\text{areaStat} > 0$) and hypomethylated

95 ($\text{areaStat} < 0$) regions were plotted against the number of CpGs located in the DMR for “Deceased vs Alive”

96 patients at admission (red indicates hypermethylated DMRs and olive green indicates hypomethylated

97 DMRs). **(C)** A total of 491,208 DMLs were detected for the “Deceased vs Alive” patient groups at follow-


98 up. Hyper and hypomethylated CpGs were plotted against their corresponding p values. **(D)** AreasStats of

99 hyper ($\text{areaStat} > 0$) and hypomethylated ($\text{areaStat} < 0$) regions were plotted against the number of CpGs

100 located in the DMR for “Deceased vs Alive” patients at follow-up.

101

A




B



103 **Suppl Figure 11: Comparison of monocytes DNA methylation at admission and follow-up.**

104 **(A)** Number and percentages of overlapping DMRs between monocytes of patients classified on the disease
105 outcome (“Deceased vs Alive”) at the time of admission and follow-up. Overall intersecting percentages
106 for both hyper and hypomethylated DMRs are shown on the left. **(B)** Gene ontology and pathway
107 enrichment analyses for DMRs at follow-up. Each bubble indicates an ontology or pathway for each of the
108 three tested databases: KEGG and Reactome pathways, and Gene Ontology. The bubble size represents the
109 percentage of genes with a corresponding significant DMR at FDR <5% and shades represent the -
110 $\log_{10}(\text{FDR})$. The total number of peaks with assigned genes per group is shown in the bar plot on the right.
111 Pathways also enriched at admission are colored in red.

112



113

114 **Suppl. Figure 12: Genes in type-1 interferon signaling GO term show increased promoter**

115 **accessibility.**

116 Box plots with normalized quantification of pileup fragments in peaks at promoter regions for “Deceased”

117 and “Alive” are shown as log2 count per million (CPM) for patient groups at admission and follow-up.

118

119 **SUPPLEMENTAL TABLES**

120 **Suppl. Table S1:** Differential gene expression analysis for each immune cell subpopulation identified by
121 scRNAseq.

122 **Suppl. Table S2:** Gene ontology and pathway enrichment analysis for differentially expressed genes per
123 sub-population.

124 **Suppl. Table S3:** Differential accessible chromatin analysis in monocytes of hospitalized COVID-19
125 patients.

126 **Suppl. Table S4:** **Suppl. Table S4:** Gene ontology and pathway enrichment analysis for differentially
127 accessible chromatin in monocytes.

128 **Suppl. Table S5:** List of differentially methylated regions in monocytes of hospitalized COVID-19
129 patients at the admission.

130 **Suppl. Table S6:** List of differentially methylated regions in monocytes of hospitalized COVID-19
131 patients at the follow-up.

132 **Suppl. Table S7:** List of genes included in the Modules Scores.

133 **Suppl. Table S8:** WGBS sequencing coverage and SNP removal statistics.

134 **Suppl. Table S9:** Intersection of gene ontology and pathway enrichment analyses.

135